Get the Stockscreener App
12.10
0.82%
-0.10
After Hours:
11.91
-0.19
-1.57%
Relay Therapeutics Inc stock is traded at $12.10, with a volume of 2.30M.
It is down -0.82% in the last 24 hours and down -27.80% over the past month.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
See More
Previous Close:
$12.20
Open:
$12.23
24h Volume:
2.30M
Relative Volume:
0.79
Market Cap:
$2.32B
Revenue:
$15.36M
Net Income/Loss:
$-276.48M
P/E Ratio:
-7.502
EPS:
-1.6129
Net Cash Flow:
$-235.87M
1W Performance:
-5.84%
1M Performance:
-27.80%
6M Performance:
+85.87%
1Y Performance:
+330.60%
1-Day Range:
$11.63
$12.57
1-Week Range:
$11.63
$13.47
52-Week Range:
$2.75
$17.32
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics Inc
Sector
Industry
Phone
617-370-8837
Address
60 HAMPSHIRE STREET, CAMBRIDGE
Compare RLAY vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
12.10 | 2.34B | 15.36M | -276.48M | -235.87M | -1.6129 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Dec-12-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Apr-17-25 | Initiated | Wells Fargo | Equal Weight |
| Sep-10-24 | Resumed | Goldman | Buy |
| Sep-10-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-10-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-20-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-19-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-23 | Initiated | Raymond James | Outperform |
| Feb-03-23 | Initiated | Oppenheimer | Outperform |
| Sep-30-22 | Initiated | Barclays | Equal Weight |
| Sep-02-22 | Initiated | Stifel | Buy |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Jul-21-21 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-08-20 | Initiated | JMP Securities | Mkt Outperform |
| Nov-05-20 | Initiated | H.C. Wainwright | Buy |
| Aug-10-20 | Initiated | Cowen | Outperform |
| Aug-10-20 | Initiated | Goldman | Buy |
| Aug-10-20 | Initiated | Guggenheim | Buy |
| Aug-10-20 | Initiated | JP Morgan | Neutral |
View All
Relay Therapeutics Inc Stock (RLAY) Latest News
Relay Therapeutics, Inc. Stock 12‑Month Price Target Raised to $21.25, Implies 74% Upside - TradingView
Relay Therapeutics Q1 2026 earnings preview - MSN
Relay Therapeutics (RLAY) price target increased by 14.03% to 21.42 - MSN
Relay Therapeutics (RLAY) surges 16.4%: Is this an indication of further gains? - MSN
Relay Therapeutics, Inc.Common Stock (NQ: RLAY - FinancialContent
Point72 Reports Zero Ownership in Relay Therapeutics (RLAY) - Stock Titan
Insider Sell Alert: Thomas Catinazzo Sells Shares of Relay Thera - GuruFocus
Relay Therapeutics CFO Catinazzo sells $227,840 in stock - Investing.com
Relay Therapeutics CFO Catinazzo sells $227,840 in stock By Investing.com - Investing.com UK
Relay Therapeutics (RLAY) CFO sells 17,717 shares in planned trade - Stock Titan
Thomas J. Catinazzo (RLAY) reports multiple 10b5-1 sales totaling tens of thousands of shares - Stock Titan
RLAY Stock Chart | RELAY THERAPEUTICS INC (NASDAQ:RLAY) - ChartMill
H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) - Yahoo Finance
How Relay’s Phase 3 Zovegalisib Breast Cancer Push Could Reshape Relay Therapeutics’ (RLAY) Investment Story - simplywall.st
Insider Monkey News - Insider Monkey
RLAY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Relay Therapeutics (NASDAQ:RLAY) Downgraded by Wall Street Zen to Sell - MarketBeat
Relay Therapeutics (RLAY) Eps Diluted (TTM) - Zacks Investment Research
Relay Therapeutics, Inc. (NASDAQ:RLAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Moomoo
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance
Relay Therapeutics, Inc. (RLAY) reports Q1 loss, lags revenue estimates - MSN
Relay Therapeutics Q1 Loss Narrows, Revenue Fall - Moomoo
Relay Therapeutics (RLAY) Q1 Loss Of US$73.3 Million Tests Growth At A Loss Narrative - Sahm
Oppenheimer Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $18 - Moomoo
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $18 to $21 - Moomoo
Relay Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates - Investing News Network
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Goldman Sachs Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Relay Therapeutics (NASDAQ:RLAY) Beats Q1 Estimates but Slips on Wider Loss and Lack of Guidance - ChartMill
Earnings Flash (RLAY) Relay Therapeutics, Inc. Reports Q1 Revenue $3.0M, vs. FactSet Est of $5.6M - marketscreener.com
Relay breast cancer drug gets FDA breakthrough, Phase 3 next - Stock Titan
Earnings Flash (RLAY) Relay Therapeutics, Inc. Reports Q1 Revenue $3.0M, Vs. FactSet Est of $5.6M - Moomoo
[10-Q] Relay Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Relay Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
FDA BTD, trial advances and 2029 cash runway for Relay Therapeutics (Nasdaq: RLAY) - Stock Titan
MSN Money - MSN
Relay Therapeutics : RLAY - 24/7 Wall St.
Relay Therapeutics Advances Zovegalisib To Phase 3 As Valuation Gap Persists - Yahoo Finance
Relay Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
$207B Market Shift: The Race for Fast Track Approval in Oncology - Quantisnow
Relay Therapeutics Inc Stock (RLAY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):